Uncovering the roots of Parkinson's disease, together
A global basic research initiative
Aligning Science Across Parkinson’s (ASAP) is fostering collaboration and resources to better understand the underlying causes of Parkinson’s disease. With scale, transparency, and open access data sharing, we believe we can accelerate the pace of discovery, and inform the path to a cure.
GP2 Launches Interactive Cohort Dashboard
As part of its mission to further understand the genetic architecture of Parkinson’s disease, GP2 is collecting diverse cohorts from around the world, with a goal of genotyping more than 150,000 volunteers. Explore GP2’s interactive cohort dashboard depicting the number of global samples completed so far, and check back often! Data will be updated quarterly.
Year in Review: A Look Back at ASAP's Accomplishments
2021 was a year of significant momentum and impact for the ASAP initiative. Check out our Year in Review page to learn more about how our network and supported programs helped advance collaboration and expand resources to accelerate and inform the path to a cure for Parkinson’s disease.
Announcing the Newest Members of the CRN
The ASAP Collaborative Research Network (CRN) continues to expand, attracting new investigators across multiple disciplines, institutions, career stages, and geographies. Working together, the CRN addresses gaps in the development and progression of Parkinson’s disease. This year, we welcome 14 new research teams who will focus their work on circuitry and brain-body interactions.
Women scientists have historically gone unrecognized for their fundamental contributions. Today and every day, GP2 recognizes and works to empower women to lead, create, and innovate in the field of PD genetics around the world.
As the demand for Parkinson’s disease genetics specialists continues to grow, GP2 is committed to providing opportunities and training to researchers around the world. With GP2’s support, the work and discoveries of our next generation of researchers will accelerate the path to a cure for PD.